Prostate Cancer

  Examining the therapeutic efficacy of targeting FAO   By examining different novel therapies there can be a better understanding of the frontline strategy for clinical management. A research team lead by Zeyad Nassar examined the main bioenergetic pathway in prostate cancer which is fatty acid oxidation (FAO). The main targeted therapies are antigen deprivation....

The vulnerable group As we know COVID-19 has drastically changed the landscape of the healthcare system and how a pandemic can truly shift target groups. COVID-19 is caused by rapid spread of acute respiratory syndrome. According to the COVID 19 data in motion, the virus has contributed to more than 440,000 deaths. This data continues...

CDk12 mutation has been closely examined in prostate cancer, possibly an immunoresponsive subgroup characterized as a high burden. The prevalence of CDK12 alterations is higher in metastatic castration-resistant prostate cancer (mCRPC; 7%) compared with primary prostate cancer (1%), which indicates an association with an aggressive phenotype. According to the American Society of Clinical Oncology study produced by...

  Diversity plays a major role in the ability to examine the impact of therapies specifically in clinical trials. Developing novel therapies within a diverse patient population has posed a challenge for the biotechnology and pharmaceutical industry as well as clinicians. There are many conflicting reasons why diversity representation is challenging even in cases where...

The MEAL Randomized Clinical Trial By Natasha Crumby Creating an environment of behavioral change can make an impact on the overall health of a patient. However, can a behavioral intervention to increase vegetable consumption really make an impact on the progression of prostate cancer? Well, this is a question investigated by the UC San Diego...

Prostate Cancer is the second most common cancer diagnosed in men worldwide. (1) Prostate Cancer treatment options  Various management options are available including surgery, radiation, and medications. Shared-decision making between healthcare providers and patients is key to choosing a prostate cancer management plan that helps promote patient satisfaction and the patient’s desired quality of life....

Decreased Participation in Prostate Clinical Trials African Americans have the highest incidence of prostate cancer, yet their participation in clinical trials related to prostate cancer is low.  The inclusion of African American men in prostate cancer trials has decreased from 11.3% in 1995 to 2.8% in 2014. (1)   Lab Miscalculation  A study reviewed a...

In the united states, there will be approximately 192,000 cases of prostate cancer in 2020 and 33,000 deaths. 1 Clinical trials are often sought in advanced cases of cancer when standard therapy is not working or not an option. Clinical trials have the benefit of providing patients with access to therapies not routinely available. Immunotherapy...

African Americans have the highest incidence of prostate cancer, yet participation in clinical trials related to prostate cancer remains low.  The inclusion of African American men in prostate cancer trials decreased from 11.3% in 1995 to 2.8% in 2014. Lab Miscalculation  A study published in JAMA Oncology  reviewed a list of prostate cancer clinical trials...